ReviewJournal of thoracic disease2026
Research progress on immune microenvironment and biomarkers of small cell lung cancer.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. SCLC is characterized by rapid proliferation, early distant metastasis, high recurrence rate, and poor prognosis, with a 5-year survival rate of less than 7%. Immune checkpoint inhibitor (ICI)-based immunotherapy has been widely applied in SCLC clinical practice, including immunotherapy combined with chemotherapy as first-line therapy, tarlatamab (post-chemo/immunotherapy) and lurbinectedin (post-platinum chemotherapy) as later-line options for extensive-stage SCLC (ES-SCLC), and chemoradiotherapy (CRT) followed by consolidation of immune therapy for limited-stage SCLC (LS-SCLC). However, the efficacy of immune combination therapy in SCLC patients remains limited and studies confirmed that objective response rate (ORR) of first-line immunochemotherapy in advanced SCLC is approximately 60-70%, while the durable response rate remains only 10-20%. The main reason lies in the complex and heterogeneous immune microenvironment of SCLC, where a network of immunosuppressive factors orchestrates an immune-excluded or "cold" phenotype. With the development of genomics application in SCLC research, increasing data have revealed and validated the immune microenvironment features of SCLC. However, there is a lack of systematic reviews in this field. This review focuses on clinical translational research across SCLC stages and subtypes, systematically summarizing the immune microenvironment features of LS-SCLC, ES-SCLC, recurrent/relapse SCLC, and never-smoker SCLC (nsSCLC) by integrating data generated from genomic sequencing, single-cell sequencing, spatial transcriptomics, and other research approaches. We summarize the biological and immune features of SCLC and highlight key biomarkers, with the goal of offering new perspectives to improve immunotherapy outcomes and uncover novel therapeutic vulnerabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.